Institutional shares held 29.7 Million
186K calls
597K puts
Total value of holdings $147M
$917K calls
$2.95M puts
Market Cap $170M
34,493,600 Shares Out.
Institutional ownership 86.08%
# of Institutions 123


Latest Institutional Activity in KMPH

Top Purchases

Q2 2025
Legal & General Group PLC Shares Held: 936K ($4.62M)
Q2 2025
Vanguard Group Inc Shares Held: 2.95M ($14.6M)
Q2 2025
Los Angeles Capital Management LLC Shares Held: 121K ($599K)
Q2 2025
Campbell & CO Investment Adviser LLC Shares Held: 83.2K ($411K)
Q2 2025
Nuveen, LLC Shares Held: 143K ($707K)

Top Sells

Q2 2025
Readystate Asset Management LP Shares Held: 112K ($551K)
Q2 2025
Aigh Capital Management LLC Shares Held: 919K ($4.54M)
Q2 2025
Stratos Wealth Partners, Ltd. Shares Held: 220K ($1.09M)
Q2 2025
Janney Montgomery Scott LLC Shares Held: 257K ($1.27M)
Q2 2025
Deutsche Bank Ag\ Shares Held: 38.5K ($190K)

About KMPH

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.


Insider Transactions at KMPH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
401K Shares
From 7 Insiders
Exercise of conversion of derivative security 390K shares
Open market or private purchase 10.8K shares
Sell / Disposition
140K Shares
From 5 Insiders
Open market or private sale 140K shares

Track Institutional and Insider Activities on KMPH

Follow KEMPHARM, INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KMPH shares.

Notify only if

Insider Trading

Get notified when an Kempharm, Inc insider buys or sells KMPH shares.

Notify only if

News

Receive news related to KEMPHARM, INC

Track Activities on KMPH